Mobile

Study To Compare The Benefit And Safety Of Luspatercept (ACE-536) Versus Placebo in subjects with lack of normal Red Blood Cells Requiring Transfusion due to myelodysplastic syndromes (MDS) with ring ...

Update Il y a 4 ans
Reference: EUCTR2015-003454-41

Study To Compare The Benefit And Safety Of Luspatercept (ACE-536) Versus Placebo in subjects with lack of normal Red Blood Cells Requiring Transfusion due to myelodysplastic syndromes (MDS) with ring sideroblasts

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To evaluate RBC transfusion independence (RBC-TI) of luspatercept compared with placebo for the treatment of anemia due to IPSS-R very low, low, or intermediate risk MDS in subjects with ring sideroblasts (≥ 15%) who require RBC transfusions

Inclusion criteria

  • Subjects with ring sideroblasts who require regular Red Blood Cell (RBC) Transfusions due to anemia due to Myelodysplastic Syndromes (MDS)

Links